THERACRYF PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 GBX | -6.67% |
|
-6.67% | -56.25% |
| May. 28 | EARNINGS AND TRADING: Victorian Plumbing profit up; Xeros loss narrows | AN |
| May. 28 | Theracryf Appoints Susan Foden As Chair | RE |
Financials (USD)
| Sales 2024 | 506K | Sales 2025 * | - | Capitalization | 3.82M |
|---|---|---|---|---|---|
| Net income 2024 | -4M | Net income 2025 * | -2M | EV / Sales 2024 | 7.86 x |
| Net cash position 2024 * | 2.38M | Net cash position 2025 * | 1.7M | EV / Sales 2025 * | - |
| P/E ratio 2024 |
-0.76
x | P/E ratio 2025 * |
-1.8
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.58% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.67% | ||
| 1 week | -6.67% | ||
| Current month | -6.67% | ||
| 1 month | -12.50% | ||
| 3 months | -36.36% | ||
| 6 months | -58.82% | ||
| Current year | -56.25% |
1 week
0.62
0.79
1 month
0.620.85
Current year
0.622.00
1 year
0.624.00
3 years
0.629.50
5 years
0.6220.25
10 years
0.6245.00
| Managers | Title | Age | Since |
|---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 62 | - |
Toni Haenninen
DFI | Director of Finance/CFO | - | 23-09-04 |
Glen Clack
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 62 | - |
Susan Foden
CHM | Chairman | 71 | 14-11-20 |
Alan Barge
BRD | Director/Board Member | - | 15-10-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 0.7 | -6.67% | 2,351,422 |
| 24-05-24 | 0.75 | 0.00% | 3,785,933 |
| 24-05-23 | 0.75 | 0.00% | 186,220 |
| 24-05-22 | 0.75 | 0.00% | 1,586,661 |
| 24-05-21 | 0.75 | 0.00% | 0 |
Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT
More quotes
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
Calendar
2024-06-13
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.25% | 4.09M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- EVG Stock
